Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RK020
- Development stage
- Preclinical
- Lead developer
- RevolKa
- Modality
- Recombinant Proteins and Enzymes
01
Overview
RK020 is a protein-based therapeutic candidate currently in the early research and development stage at RevolKa. The drug is developed using RevolKa's proprietary protein engineering platform, which utilizes directed evolution and high-throughput screening to optimize protein functions for therapeutic use. As of early 2024, RevolKa has not publicly disclosed the specific molecular target, mechanism of action, or the primary disease indication for RK020, maintaining it as part of its confidential internal pipeline.
Beyond the preview
Go deeper on RK020.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RK020.